Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 250 of 6351
-
New drug may reverse liver damage in NASH patients
Disease control OngoingThis Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Phase 3 • Sponsor: Inventiva Pharma • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptima…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radiation drug takes on chemo in prostate cancer showdown
Disease control Ongoing177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy trea…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a Chemo-Free cocktail beat early breast cancer?
Disease control OngoingThis is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous fixed-dose combination) and T-DM1, for patients wit…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a targeted drug boost standard chemo for a rare blood cancer?
Disease control OngoingThis phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-eligible patients with mantle cell lymphoma…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Spinal zaps + robotic steps: a new hope for walking after injury?
Disease control CompletedLocomotor training is often used with the aim to improve corticospinal function and walking ability in individuals with Spinal Cord Injury. Excitingly, the benefits of locomotor training may be augmented by noninvasive electrical stimulation of the spinal cord and enhance motor r…
Sponsor: City University of New York • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
MRI-Guided tweaks during radiation could spare throat cancer patients from swallowing woes
Disease control Recruiting nowThis is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adap…
Phase 2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a brain zapping headset curb relapse in addiction?
Disease control Stopped earlyThe relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold …
Sponsor: University of Minnesota • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new infusion drug calm ulcerative colitis?
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for u…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Booster shot study: can extra vaccine doses keep COVID at bay?
Vaccine CompletedSubstudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization. The study is designed to describe vaccine efficacy …
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 07:56 UTC
-
Can a new yellow fever vaccine match the old one?
Vaccine OngoingThe primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the antibody response after one dose of the YF-VAX control …
Phase 2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Heart attack aftermath: new imaging method may spot hidden danger zones better than standard tests
Disease control OngoingThe INTERCLIMA (Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome) is a multi-center, prospective, randomized trial of optical coherence tomography (OCT)-based vers…
Sponsor: Centro per la Lotta Contro l'Infarto - Fondazione Onlus • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Baby eczema cream may stop food allergies before they start
Prevention OngoingThis is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Ep…
Phase 2 • Sponsor: Kari Nadeau, MD, PhD • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC
-
Could a short pill course save hand function in advanced MS?
Disease control OngoingMS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide. Without disease modifying treatment (DMT),the majority of people with MS (pwMS) will develop significant disab…
Phase 2/3 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could hepatitis c kidneys solve the organ shortage?
Disease control CompletedThe Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients \[THINKER-NEXT\] study will include adult kidney transplant candidates without hepatitis C virus (HCV) infection on the transplant waiting list who will consent to kidney transplantation from a deceased donor i…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can an immunotherapy cocktail shrink inoperable lung tumors?
Disease control CompletedOpen-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiothera…
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a common diabetes drug slow prostate cancer progression?
Disease control OngoingThe purpose of this study is to assess the effect of the addition of metformin to abiraterone on survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. The half the patients will receive metformin in combination with androgen deprivation therapy (…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: BD0801 combo trial completed
Disease control CompletedThe standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance. In patients with platinum-resistant or refractory ovarian cancer, effective treatment options are limited and t…
Phase 3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:25 UTC
-
Sound waves could make brain tumor diagnosis safer and smarter
Diagnosis OngoingBackground: Accessing brain tumor material for pathological diagnosis requires invasive procedures that carry risk to patients including brain hemorrhages and death. Liquid biopsies are emerging non-invasive alternatives to direct tumour biopsies but the abundance of circulating…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail targets tough prostate cancer
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of a combination of nivolumab, ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate cancer (AVPC). This study will also investigate bioma…
Phase 2 • Sponsor: Andrew J. Armstrong, MD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC